Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Sponsor
Sanguine Biosciences (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05669105
Collaborator
(none)
200
1
13.3
15

Study Details

Study Description

Brief Summary

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Specimen sample

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
Actual Study Start Date :
Feb 19, 2022
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Biospecimen & Clinical Data Collection [10 years]

    Collecting biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations into the immune response can take place and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Participants willing and able to provide written informed consent

  • Participants are willing and able to provide appropriate photo identification

  • Participant's age 18 - 100 years old

  • Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)

  • Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

Exclusion Criteria:
  • Participants who are pregnant or nursing

  • Participants with a known history of HIV, hepatitis, or other infectious diseases

  • Participants who have taken an investigational product in the last 30 days

  • Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months

  • Participants currently enrolled in a clinical trial

  • Participants currently in remission

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sanguine Biosciences Waltham Massachusetts United States 02451

Sponsors and Collaborators

  • Sanguine Biosciences

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sanguine Biosciences
ClinicalTrials.gov Identifier:
NCT05669105
Other Study ID Numbers:
  • SAN-08877
First Posted:
Dec 30, 2022
Last Update Posted:
Dec 30, 2022
Last Verified:
Dec 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sanguine Biosciences
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 30, 2022